Related Experiment Video

Updated: Jul 29, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K

Codelivery of triptolide and IFN-γ to boost antitumor immunity for triple-negative breast cancer

Jianya Cai1, Minjie Zhong2, Jianhua Xu2

  • 1Department of Surgery, Quanzhou Medical College, Quanzhou, China.

International Immunopharmacology
|May 21, 2023
PubMed

Insights

Triptolide targets interferon-gamma (IFN-γ) in triple-negative breast cancer (TNBC). Combined with IFN-γ, it activates immune cells, synergistically inhibiting tumor growth.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) presents a poor prognosis and complex tumor heterogeneity.
  • The tumor microenvironment in TNBC offers potential for immunotherapy strategies.
  • Triptolide demonstrates antitumor activity, but its precise mechanism in TNBC remains unclear.

Purpose of the Study:

  • To identify the molecular mechanism of triptolide in TNBC.
  • To investigate interferon-gamma (IFN-γ) as a therapeutic target of triptolide.
  • To evaluate the combined efficacy of triptolide and IFN-γ in TNBC treatment.

Main Methods:

  • Analysis of prognostic biomarkers in TNBC to identify therapeutic targets.
  • Investigating the effect of triptolide on IFN-γ-inducible programmed death-ligand 1 (PD-L1) expression.
  • Utilizing a hydrogel delivery system for combined triptolide and IFN-γ treatment in a TNBC model.

Main Results:

  • Interferon-gamma (IFN-γ) was identified as a therapeutic target of triptolide in TNBC.
  • Triptolide significantly reversed IFN-γ-inducible programmed death-ligand 1 (PD-L1) expression.
  • Combined triptolide and IFN-γ treatment activated cytotoxic CD8+ T lymphocytes, demonstrating synergistic tumor inhibition.

Conclusions:

  • Triptolide's mechanism involves targeting IFN-γ signaling in TNBC.
  • The combination of triptolide and IFN-γ shows promising synergistic antitumor effects.
  • This approach enhances immune activation, offering a potential new immunotherapy strategy for TNBC.
Keywords:
Antitumor immunityIFN-γPD-L1Triple-negative breast cancerTriptolide

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

17.9K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
584
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K